Prediction of treatment failure using 2010 world health organization guidelines is associated with high misclassification rates and drug resistance among HIV-infected cambodian children

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 432-440

  Westley, Benjamin P ^a   Delong, Allison K ^b   Tray, Chhraing S ^c   Sophearin, Dim ^d   Dufort, Elizabeth M ^c   Nerrienet, Eric ^e   Schreier, Leeann ^a   Harwell, Joseph I ^a   Kantor, Rami ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c Angkor Hospital for Children   (Cambodia)

^d ALBANY MEDICAL COLLEGE   (United States)

^e Pasteur Institute of Cambodia   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; STAVUDINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANTIVIRAL RESISTANCE; ARTICLE; BOOTSTRAPPING; CAMBODIA; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MISCLASSIFICATION; DRUG TREATMENT FAILURE; FEMALE; GOLD STANDARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CAMBODIA; CHILD; CHILD, PRESCHOOL; CLINICAL MEDICINE; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INFANT; MALE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 84863916416     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis433     Document Type: Article

References (40)

1. UNAIDS. Global report. Available at: http://www.unaids.org/globalreport/. Accessed 23 August 2011.
2. National Institute of Statistics of Cambodia. Available at: www.nis.gov. kh. Accessed 19 January 2011.
3. Ministry of Health, Kingdom of Cambodia. Third quarterly comprehensive report, 2010. Phnom Penh, Cambodia: HIV/AIDS & STI Prevention and Care Programme, 2010.
4. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011; 13:168-73.
5. Isaakidis P, Raguenaud ME, Te V, et al. High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. J Int AIDS Soc 2010; 13:11.
6. Raguenaud ME, Isaakidis P, Zachariah R, et al. Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatr 2009; 9:54.
7. Davies MA, Moultrie H, Eley B, et al. Virologic failure and secondline antiretroviral therapy in children in South Africa - The IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011; 56:270-8.
8. Charpentier C, Gody JC, Mbitikon O, et al. Virological response and resistance profiles after 18 to 30 months of first-or second/third-line antiretroviral treatment: a cross-sectional evaluation in HIV-1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses 2011; 28:87-94.
9. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-20.
10. Ruel TD, Kamya MR, Li P, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011; 56:44-50.
11. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-11.
12. Ministry of Health, Kingdom of Cambodia. National guidelines for the use of pediatric antiretroviral therapy in Cambodia. Phnom Penh, Cambodia: Ministry of Health, 2007.
13. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access, recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2006.
14. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-7.
15. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Iinfect Dis 2009; 49: 454-62.
16. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis 2007; 11:413-6.
17. Meya D, Spacek LA, Tibenderana H, et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009; 12:3.
18. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
19. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14:856-61.
20. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access, recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2010.
21. Ministry of Health, Kingdom of Cambodia. National guidelines for the use of pediatric antiretroviral therapy in Cambodia. Phnom Penh, Cambodia: Ministry of Health, 2011.
22. Delong AK, Wu M, Bennett D, et al. Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retroviruses 2011; PMID: 21916749. doi:10.1089/aid.2011.0120.
23. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-800.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-63.
25. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380-8.
26. Lan NT, Recordon-Pinson P, Hung PV, et al. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 study. Large predominance of CRF01-AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses 2003; 19:925-8.
27. Team RDC. R: A language and environment for statistical computing. Available at: http://www.R-project.org/Accessed 15 August 2011.
28. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2010.
29. Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr 2010; 54:368-75.
30. Dufort E, Nyandiko W, DeLong A, et al. Misclassification of treatment failure using immunologic and clinical monitoring in HIV infected children and adolescents in western Kenya. In: Program and abstracts of the 48th annual meeting of IDSA (Vancouver, BC, Canada). 2010. Arlington, VA: IDSA, 2010.
31. Davies MA, Boulle A, Eley B, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy-the IeDEA Southern Africa collaboration. Trop Med Int Health 2011; doi:10.1111/j.13653156.2011.02854.x.
32. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
33. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on firstline treatment. Pediatr Infect Dis J 2011; 30:52-6.
34. Zhao Y, Mu W, Harwell J, et al. Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr 2011; 58:47-53.
35. Oliveira R, Krauss M, Essama-Bibi S, et al. Viral load predicts new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis 2010; 51:1325-33.
36. Schneider K, Puthanakit T, Kerr S, et al. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS 2011; 25:1143-51.
37. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007; 120:e1134-40.
38. Abouyannis M, Menten J, Kiragga A, et al. Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa. AIDS 2011; 25:1627-35.
39. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis 2011; 52:264-70.
40. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-50.